Efficacy and safety of decitabine combined with low-dose cytarabine, aclarubicin, and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation  

作　　者：Si-Si Chen Qian Sun Lan Cao Wen-Zhong Wu Yue Xie Chun Qiao Jian-yong Li Si-Xuan Qian Ming Hong 

机构地区：[1]Department of Hematology,The Affiliated Yixing Hospital of Jiangsu University,Wuxi,Jiangsu 214200,China [2]Department of Hematology,The First Affiliated Hospital of Nanjing Medical University,Jiangsu Province Hospital,Nanjing,Jiangsu 210029,China [3]Key Laboratory of Hematology of Nanjing Medical University,Nanjing,Jiangsu 210029,China [4]Collaborative Innovation Center for Cancer Personalized Medicine,Nanjing,Jiangsu 210029,China [5]Pukou CLL Center,Pukou division of Jiangsu Province Hospital,Nanjing,Jiangsu 211899,China

出　　处：《Chinese Medical Journal》2021年第12期1477-1479,共3页中华医学杂志（英文版）

基　　金：supported by the National Natural Science Foundation of China(Nos.81870119 and 81720108002);the National Science and Technology Major Project(No.2018ZX09734007);the Clinical Medicine and Technological Development Foundation of Jiangsu University(No.JLY20180072).

摘　　要：Tumor suppressor gene P53(TP53)is a critical tumor suppressor gene.The mutant p53 protein enhances the activity,invasion and metastasis of tumor cells.Acute myeloid leukemia(AML)patients with TP53 mutations respond poorly to conventional chemotherapy and have poor clinical outcomes.We previously conducted a multi-center phase II clinical trial(No.ChiCTRONC-11001700)in elderly AML patients with decitabine,low-dose cytarabine,aclarubicin,and granulocyte colony-stimulating factor(G-CSF)(DCAG regimen),which showed an overall response rate(ORR)of 82.4%and a complete remission(CR)rate of 64.7%.[1]Given this satisfactory effect of DCAG regimen,the present study has been designed to compare the efficacy and safety of DCAG regimen with standard therapy in AML patients with TP53 mutations.

关 键 词：TP53 PATIENTS stimulating 

分 类 号：R733.7[医药卫生—肿瘤]